Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty

American Journal Geriatric Pharmacotherapy

Volumn 5, Issue 3, 2007, Pages 177-184

  Mini, Louis J ^a   Wang Weigand, Sherry ^a   Zhang, Jeff ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

Author keywords

elderly; insomnia; melatonin receptor agonist

Indexed keywords

PLACEBO; RAMELTEON;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSGEUSIA; ELDERLY CARE; EYE PAIN; FATIGUE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SLEEP TIME; TREATMENT DURATION; XEROSTOMIA;

AGED; CHRONIC DISEASE; DIZZINESS; DOUBLE-BLIND METHOD; DYSGEUSIA; FEMALE; HEADACHE; HUMANS; HYPNOTICS AND SEDATIVES; INDENES; MALE; MUSCULAR DISEASES; PAIN; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME FACTORS;

EID: 35748932915     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2007.09.004     Document Type: Article

References (53)

1. Foley D., Ancoli-Israel S., and Britz P. Walsh J. Sleep disturbances and chronic disease in older adults: Results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res 56 (2004) 497-502
2. Foley D., Monjan A., and Simonsick E. et al. Incidence and remission of insomnia among elderly adults: An epidemiologic study of 6,800 persons over three years. Sleep 22 Suppl 2 (1999) S366-S372
3. Ford D. Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 262 (1989) 1479-1484
4. Simon G., and VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 154 (1997) 1417-1423
5. Foley D., Monjan A., and Brown S. et al. Sleep complaints among elderly persons: An epidemiologic study of three communities. Sleep 18 (1995) 425-432
6. Ganguli M., and Reynolds C. Gilby JE. Prevalence and persistence of sleep complaints in a rural older community sample: The MoVIES project. J Am Geriatr Soc 44 (1996) 778-784
7. Roth T., and Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. II. Sleep 22 Suppl 2 (1999) S354-S358
8. Ancoli-Israel S., and Roth T. Characteristics of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. I. Sleep 22 Suppl 2 (1999) S347-S353
9. Roth T. Prevalence, associated risks, and treatment patterns of insomnia. J Clin Psychiatry 66 Suppl 9 (2005) 10-13
10. Ancoli-Israel S., and Cooke J. Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. J Am Geriatr Soc 53 Suppl 7 (2005) S264-S271
11. Wagner A., Zhang F., Soumerai S., et al. Benzodiazepine use and hip fractures in the elderly: Who is at greatest risk?. Arch Intern Med 164 (2004) 1567-1572
12. Allain H., Bentue-Ferrer D., Polard E., et al. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: A comparative review. Drugs Aging 22 (2005) 749-765
13. Roehrs T., Merlotti L., Zorick F., and Roth T. Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berl) 116 (1994) 130-134
14. Terzano M., Rossi M., Palomba V., et al. New drugs for insomnia: Comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 26 (2003) 261-282
15. Wang P., Bohn R., Glynn R., et al. Zolpidem use and hip fractures in older people. J Am Geriatr Soc 49 (2001) 1685-1690
16. Hajak G., Muller W., Wittchen H., et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: A review of case reports and epidemiological data. Addiction 98 (2003) 1371-1378
17. Griffiths R., and Weerts E. Benzodiazepine self administration in humans and laboratory animals- implications for problems of long-term use and abuse. Psychopharmaeology (Berl) (1997) 134-137
18. Roehrs T., and Roth T. 'Hypnotic' prescription patterns in a large managed-care population. Sleep Med 5 (2004) 463-466
19. Basu R., Dodge H., Stoehr G., and Ganguli M. Sedativehypnotic use of diphenhydramine in a rural, older adult, community-based cohort: Effects on cognition. Am J Geriatr Psychiatry 11 (2003) 205-213
20. Jackson W., Roose S., and Glassman A. Cardiovascular toxicity of antidepressant medications. Psychopathology 20 Suppl 1 (1987) 64-74
21. Gershon S. Comparative side effect profiles of trazodone and imipramine: Special reference to the geriatric population. Psychopathology 17 Suppl 2 (1984) 39-50
22. Agostini J., Leo-Summers L., and Inouye S. Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med 161 (2001) 2091-2097
23. Kamel N., and Gammack J. Insomnia in the elderly: Cause, approach, and treatment. Am J Med 119 (2006) 463-469
24. Woodward M. Insomnia in the elderly. Aust Fam Physician 28 (1999) 653-658
25. Liu C., Weaver D., Jin X., et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 19 (1997) 91-102
26. Kato K., Hirai K., Nishiyama K., et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/ MT2 receptor agonist. Neuropharmacology 48 (2005) 301-310
27. Barrett P., Conway S., and Morgan P. Digging deep-structure-function relationships in the melatonin receptor family. J Pineal Res 35 (2003) 221-230
28. Dubocovich M., Rivera-Bermudez M., Gerdin M., and Masana M. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci. 8 (2003) d1093-d1108
29. US Dept of Justice Drug Enforcement Administration. Lists of scheduling actions, controlled substances, and regulated chemicals. Published April, 2007 Available at: (September 4, 2007). http://www.deadiversion.usdoj.gov/schedules/orangebook2007.pdf Accessed
30. Karim A., Tolbert D., and Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 46 (2006) 140-148
31. Greenblatt D., Harmatz J., and Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol 47 (2007) 485-496
32. Roth T., Selden D., Wang-Weigand S., and Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 23 (2007) 1005-1014
33. Richardson G., Wang-Weigand S., Zhang J., and DeMicco M. Long-term safety of ramelteon treatment in adults with chronic insomnia [abstract]. Sleep 29 Suppl (2006) A233
34. Richardson G., Wang-Weigand S., Sainati S., and Demissie S. Long-term effects of ramelteon on endocrine function in patients with chronic insomnia in a double-blind, placebo-controlled phase III study [abstract]. Clin Pharmacol Ther 79 (2006) P68
35. Roth T., Stubbs C., and Walsh J. Ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. [published correction appears in Sleep. 2006;29:417]. Sleep 28 (2005) 303-307
36. Zammit G., Schwartz H., Roth T., et al. Effect of ramelteon, a selective MT1/MT2 receptor agonist, in a first-night-effect model of transient insomnia [abstract]. Sleep 29 Suppl (2006) A238
37. Zammit G., Roth T., Erman M., et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia [abstract]. Sleep 28 Suppl (2005) A228-A229
38. Roth T., Seiden D., Sainati S., et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 7 (2006) 312-318
39. Erman M., Seiden D., Zammit G., et al. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 7 (2006) 17-24
40. Johnson M., Suess P., and Griffiths R. Ramelteon: A novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 63 (2006) 1149-1157
41. DeMicco M., Wang-Weigand S., and Zhang J. Long-term therapeutic effects of ramelteon treatment in adults with chronic insomnia: A 1-year study [abstract]. Sleep 29 Suppl (2006) A234
42. US Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. 27th edition (published 2007) Available at: (September 4, 2007). http://www.fda.gov/cder/orange/obannual.pdf Accessed
43. National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 28 (2005) 1049-1057
44. Hughes R., Sack R., and Lewy A. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: Assessment in a clinical trial of melatonin replacement. Sleep 21 (1998) 52-68
45. Garfinkel D., Laudon M., Nof D., and Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 346 (1995) 541-544
46. Haimov I., Lavie P., Laudon M., et al. Melatonin replacement therapy of elderly insomniacs. Sleep 18 (1995) 598-603
47. Zhdanova I., Wurtman R., Regan M., et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 86 (2001) 4727-4730
48. Baskett J., Broad J., Wood P., et al. Does melatonin improve sleep in older people? A randomised crossover trial. Age Ageing 32 (2003) 164-170
49. Buscemi N., Vandermeer B., Hooton N., et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 20 (2005) 1151-1158
50. Almeida Montes L., Ontiveros Uribe M., Cortes Sotres J., and Heinze Martin G. Treatment of primary insomnia with melatonin: A double-blind, placebo-controlled, crossover study. J Psychiatry Neurosci 28 (2003) 191-196
51. Morin C., Bootzin R., Buysse D., et al. Psychological and behavioral treatment of insomnia: Update of the recent evidence (1998-2004). Sleep 29 (2006) 1398-1414
52. Sivertsen B., Omvik S., Pallesen S., et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: A randomized controlled trial. JAMA 295 (2006) 2851-2858
53. Jacobs G., Pace-Schott E., Stickgold R., and Otto M. Cognitive behavior therapy and pharmacotherapy for insomnia: A randomized controlled trial and direct comparison. Arch Intern Med 164 (2004) 1888-1896